Compounded semaglutide is still legal in the US only in narrow cases: a 503A pharmacy may compound it for an individual patient when a prescriber documents a significant clinical difference from Wegovy or Ozempic. FDA's 18 September 2026 warning letter to Empower Pharmacy said semaglutide with added vitamin B12 "appear to be essentially copies" and that the volume made the differences look "pretextual". FDA's proposal to keep semaglutide off the 503B bulks list is still awaiting a final decision; comments closed on 30 July 2026.
Comparing the two compounds themselves rather than their legal status? See tirzepatide vs semaglutide.
What we read
FDA drug shortage database historical entries for semaglutide (Wegovy, Ozempic) from 2022 through April 2026; the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting minutes from October 2024 and April 2026; Section 503A of the Federal Food, Drug, and Cosmetic Act; the public partner-program pages of compounded-GLP-1 telehealth providers (Hims, Ro, Mochi, Henry, Eden); and contemporaneous trade-press coverage through Q1 2026.
Is compounded semaglutide still legal in 2026?
Yes, but only in narrow cases. A 503A pharmacy may compound semaglutide for an identified patient when the prescriber documents a significant difference from the approved product. FDA's enforcement discretion for semaglutide copies ended on 24 April 2025, according to footnote 3 of the Empower letter. Since 18 September 2026 FDA has said in writing that adding vitamin B12 does not meet that test when the volume suggests mass production. Outsourcing facilities (503B) face a separate proposal, still pending, that would keep semaglutide off their bulks list.
The short version
Compounded semaglutide is a closed mass-market channel as of October 2026. The shortage exemption that supported it ended when FDA resolved the semaglutide shortage, and the Empower letter closed the workaround many pharmacies used afterwards. Telehealth providers that built the category in 2022–2024 have either exited the line, moved to brand-only prescriptions, or kept compounded options that now carry a documented clinical reason.
The longer version below explains how the legal channel opened, why it closed, and what the October 2026 status is.
How the channel opened — the shortage-exemption door
Section 503A of the FDCA is the law that lets traditional compounding pharmacies prepare individualized prescriptions for specific patients without going through full new-drug-application review. It exists because clinical practice sometimes requires formulations the brand manufacturer doesn't make.
The 503A exemption comes with conditions. One of them: a 503A pharmacy cannot compound a near-identical version of an FDA-approved drug just because the patient prefers it. The compounded version must serve a clinical need the brand product doesn't meet.
There is a narrow exception. If the brand product is in FDA-confirmed shortage, compounded versions become permissible during the shortage period. This shortage exemption is the door through which compounded semaglutide entered the legal telehealth channel.
Wegovy entered FDA-confirmed shortage in March 2022. The combination of high demand and limited Novo Nordisk manufacturing capacity created a multi-month, then multi-year, shortage. Compounded versions became legally available, and a category of telehealth provider emerged to use that exemption commercially:
- Hims & Hers — compounded semaglutide via partner pharmacy network
- Ro Body — compounded semaglutide
- Mochi Health — compounded GLP-1 (initially semaglutide; later shifted toward tirzepatide)
- Henry Meds — compounded semaglutide
- Eden — compounded semaglutide
Combined monthly active patient base across this category reportedly peaked at hundreds of thousands in 2024.
How the channel is closing — three forces
Three regulatory and market forces are closing the channel simultaneously. They are not coordinated; they happen to compound.
Force 1 — Brand availability normalized
Through 2024 and into 2025, Novo Nordisk completed manufacturing capacity expansions for semaglutide products. The FDA-confirmed shortage status began to wind down as brand product became reliably available again. Once a brand product is no longer in confirmed shortage, the 503A shortage exemption no longer covers compounded versions of that compound.
FDA's enforcement discretion for compounded semaglutide copies ended on 24 April 2025, and for tirzepatide on 5 March 2025, per footnote 3 of the Empower letter. Compounded versions that operated under the shortage exemption lose their legal cover when the shortage is formally declared over.
Force 2 — PCAC reaffirmed restrictions on the GLP-1 class
The October 2024 PCAC vote recommended adding tirzepatide to the 503A do-not-compound list, citing safety and efficacy concerns specific to compounded versions during the shortage period. The April 2026 PCAC meeting reaffirmed compounding restrictions on the GLP-1 class as a whole.
The PCAC track does not directly bind compounding pharmacies until the FDA acts on the recommendation, and that process can take months to years. But the policy direction is now clear: the FDA has formally signaled that compounded GLP-1 versions are not in scope for routine 503A use. See our 503A and PCAC analysis for the full mechanism.
Force 3 — Telehealth providers pivoted
Faced with simultaneous pressure on the brand-availability and PCAC tracks, telehealth providers responded differently:
- Hims & Hers retained a compounded semaglutide line where patient-specific formulations qualify (e.g., dose adjustments beyond brand-product strengths) but expanded brand-prescription pathways
- Ro Body shifted toward brand-prescription-first with compounded options as exception cases
- Mochi Health pivoted toward tirzepatide before the PCAC reaffirmation extended restrictions to that compound; subsequent positioning is in flux
- Eden and Henry Meds retained compounded options where patient-specific clinical needs justify them, but with narrower scope than the 2022–2024 mass-market positioning
The mass-market compounded-semaglutide telehealth offering of 2024 is not the May 2026 reality. The category exists in narrower patient-specific forms, not as a routine alternative to brand product.
Does adding B12 make compounded semaglutide legal?
Not by itself. After the shortage ended, many 503A pharmacies kept shipping semaglutide with an added ingredient, most often vitamin B12 (cyanocobalamin), and treated the addition as the patient-specific difference the law requires. FDA's warning letter 738238 to Empower Pharmacy in Houston, dated 18 September 2026 and posted 22 September, is FDA's first written answer to that model:
- Empower's "SEMAGLUTIDE/CYANOCOBALAMIN (1 ML)(5/0.5 MG/ML)" and two tirzepatide/niacinamide products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products."
- "The volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual." The monthly order counts are redacted in the published letter.
- Prescriber statements of significant difference appeared "repeated verbatim across many records", and some came through third-party platforms offering "pre-selected menu options."
Empower told CBS News it had "already remedied many of the issues outlined in the Warning Letter" (CBS, 24 September 2026). The letter is not a court ruling, and the Alliance for Pharmacy Compounding argues that volume alone is not a violation. But a pharmacy shipping semaglutide/B12 at scale now knows FDA's position.
On r/tirzepatidecompound the thread "New FDA Warning Letter issued to Empower Pharmacy" became the place patients asked whether their own prescriptions were next. The practical answer: ask your prescriber what the documented clinical reason for the compounded version is. If the answer is "it has B12", FDA has now said that is not enough.
Is the gray market a substitute for a compounding pharmacy?
No, and the August letters made the gap wider. Reddit's "Grey market vs compounding pharmacies" thread frames it as a price choice. Legally it is a different category. A 503A pharmacy fills a prescription under state board and FDA oversight. A research-peptide vendor sells unapproved product labelled "not for human use". FDA's five warning letters dated 24 August 2026 named semaglutide SKUs at four such vendors, including "GLP-1 S" and "GLP-1 SEM", as unapproved new drugs (enforcement timeline).
A legal oral option now exists in the UK. The MHRA authorised orforglipron (Foundayo) for weight management and type 2 diabetes on 10 August 2026, the first authorisation in Europe.
The October 2026 legal-access matrix
Where buyers can legally access semaglutide as of 5 October 2026:
| Channel | Status | Notes |
|---|---|---|
| Brand prescription (Wegovy, Ozempic) | Available | Standard insurance + cash-pay channels |
| Compounded via 503A pharmacy | Severely restricted | Documented patient-specific significant difference required; FDA called B12 blends at volume "pretextual" on 18 Sep 2026 |
| 503B outsourcing facility compounded | Restricted | FDA proposed on 30 Apr 2026 to keep semaglutide off the 503B bulks list; comments closed 30 Jul 2026; no final determination as of 5 Oct 2026 |
| Telehealth-compounded mass-market | Largely closed | Providers pivoted to brand-prescription-first |
| Trial enrollment | Where available | Mostly closed for new semaglutide trials |
| Research-peptide channel | Outside legal access framework | Not a substitute; different legal category entirely |
What this means for the buyer
If you previously accessed compounded semaglutide through a mass-market telehealth provider: the channel that supplied that prescription has likely either narrowed or closed. The brand prescription pathway is the cleanest current alternative where eligible.
If your provider still offers compounded semaglutide: confirm the clinical justification with them. Patient-specific compounded formulations remain legal where the brand product genuinely doesn't meet a clinical need (e.g., dose adjustments not available in brand strengths, allergen avoidance). Routine substitution is no longer covered by the shortage exemption.
If you're considering the research-peptide channel as a substitute: the channels are legally distinct. Research-peptide semaglutide is governed by FDA misbranding authority (see our FDA peptide enforcement timeline), not by 503A. The September 2025 Warning Letter sweep specifically targeted vendors making drug claims for compounded-equivalent products, and the August 2026 letters named semaglutide under vendor code names. Vendor compliance posture matters.
What's likely next
Two forward indicators that will move the channel further over 2026–2027:
Re-shortage scenarios. If brand semaglutide re-enters confirmed shortage — manufacturing disruption, demand spike, supply chain event — the 503A shortage exemption could re-open partially for that compound. The April 2026 PCAC reaffirmation makes a partial re-opening narrower than the 2022–2024 window, but the door is not permanently sealed.
Brand pricing competition. The structural reason compounded semaglutide had mass-market demand was price differential against brand. As brand-product list and net prices adjust, the demand pressure on alternative channels (compounded, research-peptide) adjusts with them. This is a market force, not a regulatory one, and harder to predict.
What we did not address
This article addresses the legal-channel status. It does not address:
- Clinical decision-making about whether semaglutide is appropriate for an individual — that is between a buyer and their prescriber.
- Comparative efficacy of compounded vs. brand product when both were available — see published literature for this.
- Specific pricing at any individual telehealth provider — these change frequently; check the provider directly.
- Tirzepatide and retatrutide — covered separately. Tirzepatide is on a similar regulatory trajectory; retatrutide is not eligible for compounding regardless of approval status.
Sources
- FDA drug shortage database — historical semaglutide shortage status
- FDA PCAC meeting materials
- FDA warning letter 738238, Empower Pharmacy, 18 September 2026
- Federal Register 2026-12937, 503B bulks comment extension to 30 July 2026; original notice 2026-08552
- CBS News, 24 September 2026, Empower response
- Alliance for Pharmacy Compounding, 25 September 2026
- MHRA orforglipron authorisation, 10 August 2026
- Section 503A of the FDCA — FDA overview
- Internal: 503A and PCAC compounding analysis, FDA peptide enforcement, 2024–2026, Retatrutide vs Tirzepatide research comparison, longevity telehealth platforms
Frequently asked
Is compounded semaglutide still legal in 2026?
Only in narrow, patient-specific cases. FDA ended its enforcement discretion for semaglutide copies on 24 April 2025. Since then a 503A pharmacy may compound it only where a prescriber documents a significant difference for an identified patient. FDA has proposed keeping semaglutide off the 503B bulks list; no final decision had been published as of 5 October 2026.
Does adding B12 make compounded semaglutide legal?
Not on its own. In its 18 September 2026 letter to Empower Pharmacy, FDA said semaglutide/cyanocobalamin and tirzepatide/niacinamide products "appear to be essentially copies" of approved drugs, and that the volume produced suggests the differences "are pretextual". FDA wants a documented, patient-specific reason for each prescription, not an added vitamin.
Can a telehealth platform's menu supply the medical reason?
FDA doubts it. The Empower letter questions significant-difference statements "repeated verbatim across many records" and prescriptions generated through platforms "that provide prescribers with pre-selected menu options." FDA said those practices call into question whether the 503A conditions are met. A reason picked from a dropdown is the pattern FDA flagged.
What is the 503B bulks list proposal for semaglutide?
On 30 April 2026 FDA proposed not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list, which would let outsourcing facilities compound them from bulk ingredient. The comment period was extended to 30 July 2026 (docket FDA-2018-N-3240). FDA must publish a final determination in the Federal Register; we had found none by 5 October 2026.
Is research-peptide semaglutide a substitute for compounded semaglutide?
Legally, no. A 503A pharmacy fills a prescription under state and federal pharmacy law. A research-peptide vendor sells unapproved product labelled "not for human use", and FDA's August 2026 warning letters named semaglutide SKUs at four such vendors as unapproved new drugs. Nobody verifies the dose or sterility of a gray-market vial before it ships.